Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias

Pharmacotherapy

Volumn 17, Issue 2 SUPPL., 1997, Pages

  Nolan Jr , Paul E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BRETYLIUM; CIMETIDINE; CIPROFLOXACIN; CODEINE; CYTOCHROME P450; DIGOXIN; ERYTHROMYCIN; LIDOCAINE; METOPROLOL; METRONIDAZOLE; MEXILETINE; OROSOMUCOID; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; WARFARIN;

ANTIARRHYTHMIC ACTIVITY; CONFERENCE PAPER; DRUG EFFECT; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BIOTRANSFORMATION; BRETYLIUM COMPOUNDS; ELECTROCARDIOGRAPHY; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, INTRAVENOUS; LIDOCAINE; PROCAINAMIDE; QUINIDINE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 1842327977     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (107)

1. Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13(2):442-9.
2. Mason JW, and the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
3. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92(1):3264-72.
4. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996;27:67-75.
5. Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990;263:1106-13.
6. Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990;48:503-8.
7. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987;39:1-47.
8. Buchert E, Woosley RL. Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics 1992;2:2-11.
9. Eichelbaum M, Gross AS. Stereochemical aspects of drug action and disposition. Adv Drug Res 1996;28:1-64.
10. Nolan PE, Mayersohn M. Fenster PE, Bliss M. Single-dosed pharmacokinetics of amiodarone [abstr]. Drug Intell Clin Pharm 1985;19:463.
11. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983;106(4 pt 2):840-7.
12. Falik R, Flores BT, Shaw L, et al. Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. Am J Med 1987;82:1102-8.
13. Harris L, Hind CR, McKenna WJ, et al. Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J 1983;59(693):440-2.
14. Ujhelyi MR, Klamerus KJ, Vadiei K, et al. Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J Clin Pharmacol 1996;36(2): 122-30.
15. Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y. Evidence of CYP3A mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993;21:978-85.
16. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics, and clinical effects. J Am Coll Cardiol 1984;3:1059-71.
17. Stark G, Stark U, Windisch M, et al. Comparison of acute electrophysiological effects of amiodarone and its metabolite desethylamiodarone in Langedorff perfused guinea pig hearts. Basic Res Cardiol 1991;86(2):136-47.
18. Nattel S, Davies M, Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 1988;77(1):200-8.
19. Abdollah H, Brien JF, Brennan FJ. Antiarrhythmic effects of desethylamiodarone in dogs with subacute myocardial infarction and inducible ventricular arrhythmias. J Cardiovasc Pharmacol 1989;13(1):37-44.
20. Vadiei K, O'Rangers EA, Klamerus KJ, et al. Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol 1996;36:720-7.
21. Zimmerman JJ, Klamerus KJ, Giel S, et al. Effect of age on amiodarone disposition [abstr]. Clin Pharmacol Ther 1993;53:201.
22. Veronese ME, McLean S, Hendriks R. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass binding method. Br J Clin Pharmacol 1988;26:721-31.
23. Otto MD, Nolan PE, Hoyer GL, Fenster PE. Characterization of amiodarone protein binding [abstr]. Pharmacotherapy 1992;12:255.
24. Lesko LJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet 1989;17(2):130-40.
25. Funck-Brentano C, Jacqz-Aigrain E, Leenhardt A, et al. Influence of amiodarone on genetically determined drug metabolism in humans. Clin Pharmacol Ther 1991;50: 259-66.
26. Heimark LD, Wienkers L, Kunze KJ, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51:398-407.
27. Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetics interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther 1989;46:43-50.
28. Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. Am J Cardiol 1990;65:1252-7.
29. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991;31:125-30.
30. Singh BN. Acute management of ventricular arrhythmias: role of antiarrhythmic agents. Pharmacotherapy. 1997;17(2 Pt 2):56S-64.
31. Mostow ND, Vrobel TR, Noon D, Rakita L. Intravenous amiodarone: hemodynamics, pharmacokinetics, electrophysiology, and clinical utility. Clin Prog Electrophysiol Pac 1986;4(4):342-57.
32. Cote P, Bourassa MG, Delaye J, et al. Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease. Circulation 1979;59:1165-72.
33. Munoz A, Karila P, Gallay P, et al. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 1988;9(2):142-8.
34. Schwartz A, Shen E, Morady F, et al. Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. Am Heart J 1983;106:848-56.
35. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:839-74.
36. Anderson JL, Patterson E, Wagner JG, et al. Oral and intravenous bretylium disposition. Clin Pharmacol Ther 1980;28(4):468-78.
37. Anderson JL, Patterson E, Conlon M, Pasyk S, Pitt B, Lucchesi BR. Kinetics of antifibrillatory effects of bretylium: correlation with myocardial drug concentrations. Am J Cardiol 1980;46(4):583-92.
38. Garrett ER, Green JR, Bialer M. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Biopharm Drug Dispos 1982;3:128-64.
39. Josselson J, Narang PK, Adir J, Yacobi A, Sadler JH. Bretylium kinetics in renal insufficiency. Clin Pharmacol Ther 1983;33(2):144-50.
40. Anderson JL, Brodine WN, Patterson E, et al. Serial electrophysiologic effects of bretylium in man and their correlation with plasma concentrations. J Cardiovasc Pharmacol 1982;4(6):871-82.
41. Anderson JL. Bretylium tosylate: profile of the only available class 111 antiarrhythmic agent. Clin Ther 1985;7(2):205-24.
42. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92(11):3255-63.
43. Puddu PE, Jouve R, Saadjian A, Torresani J. Experimental and clinical pharmacology of bretylium tosylate in acute myocardial infarction: a 15-year journey. J Pharmacol 1986;17(3):223-43.
44. Stenson RE, Constantino RT, Harrison DC. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 1971;43:205-11.
45. Rowland M, Thomson PD, Guichard A, et al. Disposition kinetics of lidocaine in normal subjects. Ann NY Acad Sci 1971;179:383-98.
46. Sawyer DR, Ludden TM, Crawford MH. Continuous infusion of lidocaine in patients with cardiac arrhythmias. Arch Intern Med 1981;141:43-5.
47. LeLorier J, Grenon D, Latour Y, et al. Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. Ann Intern Med 1977;87(6):700-6.
48. Bargetzi MJ, Aoyama T, Gonzalez, FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989;46:521-7.
49. Saville BA, Gray MR, Tam YK. Evidence for lidocaine-induced enzyme inactivation. J Pharm Sci 1989;78:1003-8.
50. Thomson AH, Elliott HE, Kelman AW, et al. The pharmacokinetics and pharmacodynamics of lidocaine and MEGX in healthy subjects. J Pharmacokinet Biopharm 1987;15:101-15.
51. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78(4): 499-508.
52. Routledge PA, Stargel WW, Wagner GS, et al. Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med 1980;93:701-4.
53. 1-acid glycoprotein concentration to plasma protein binding of lidocaine. Clin Pharmacol Ther 1990;47:366-70.
54. Feely J. Wilkinson GR, McAllister CB, Wood AJ. Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med 1982;96(5):592-4.
55. Nies AS, Shand DG, Wilkinson GR. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1976;1(2):135-55.
56. Fruncillo RJ, Kozin SH, DiGregorio GJ. Effect of amiodarone on the pharmacokinetics of phenytoin, quinidine, and lidocaine in the rat. Res Commun Chem Pathol Pharmacol 1985;50(3):451-4.
57. Siegmund JB, Wilson JH, Imhoff TE. Amiodarone interaction with lidocaine. J Cardiovasc Pharmacol 1993;21(4):513-15.
58. Armengol R, Graff J, Baerman JM, et al. Lack of effectiveness of lidocaine for sustained, wide QRS complex tachycardia. Ann Emerg Med 1989;18:254-7.
59. Griffith MJ, Linker NJ, Garratt CJ, et al. Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. Lancet 1990;336:670-3.
60. Ho DSW, Zecchin RP, Richards DAB, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994;344:18-23.
61. Gorgels APM, Van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996;78:43-6.
62. Pieper JA, Slaughter RL, Anderson GD, Wyman MG, Lalka D. Lidocaine clinical pharmacokinetics. Drug Intell Clin Pharm 1982;16(4):291-4.
63. Graffner C, Johnsson G, Sjogren J. Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Clin Pharmacol Ther 1975;17(4):414-23.
64. Koch-Weser J. Pharmacokinetics of procainamide. Ann NY Acad Sci 1971;179:370-82.
65. Coyle JD, Boudoulas H, MacKichan JJ, Lima JJ. Concentration-dependent clearance of procainamide in normal subjects. Biopharm Drug Dispos 1985;6:159-65.
66. Roden DM, Reele SB, Higgins SB, et al. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 1980;46(3):463-8.
67. Drayer DE, Lowenthal DT, Woosley RL, et al. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Clin Pharmacol Ther 1977;22(1):63-9.
68. Bauer LA, Black D, Gensler A, Sprinkle J. Influence of age, renal function and heart failure on procainamide clearance and N-acetylprocainamide serum concentrations. Int J Clin Pharmacol Ther Toxicol 1989;27(5):213-16.
69. Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet 1984;9(6):545-54.
70. Tisdale JE, Rudis MI, Padhi ID, et al. Disposition of procainamide in patients with chronic congestive heart failure. J Clin Pharmacol 1996;36:35-41.
71. Kessler KM, Kayden DS, Estes DM, et al. Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. J Am Coll Cardiol 1986;7(5):1131-9.
72. Giardina EG. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias. Ann N Y Acad Sci 1984;432:177-88.
73. Bauer LA, Black D, Gensler A. Procainamide-cimetidine drug interaction in elderly male patients. J Am Geriatr Soc 1990;38(4):467-9.
74. Windle J, Prystowsky EN, Miles WM, Heger JJ. Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther 1987;41(6):603-10.
75. Saal AK, Werner JA, Greene HL, Sears GK, Graham EL. Effect of amiodarone on serum quinidine and procainamide levels. Am J Cardiol 1984;53(9):1264-7.
76. Myerburg RJ, et al. Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of ventricular complexes and prevention of recurrent ventricular tachycardia. Circulation 1981;64:280-90.
77. Koch-Weser J, Klein SW. Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 1971;215:1454-60.
78. Greenspan AM, et al. Large-dose procainamide therapy for ventricular tachyarrhythmias. Am J Cardiol 1980;46:453-62.
79. Marchlinski FE, Buxton AE, Josephson ME, Schmitt C. Predicting ventricular tachycardia cycle length after procainamide by assessing cycle length-dependent changes in paced QRS Duration. Circulation 1989;79(1):39-46.
80. Rea RF, Hamdan M, Schomer SJ, Geraets DR. Inhibitory effects of procainamide on sympathetic nerve activity in humans. Circ Res 1991;69(2):501-8.
81. Sharma AD, Purves P, Yee R, et al. Hemodynamic effects of intravenous procainamide during ventricular tachycardia. Am Heart J 1990;119:1034-41.
82. Bolme P, Otto U. Dose-dependence of the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1977;12(1):73-6.
83. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P450. Mol Pharmacol 1986;30:287-95.
84. Ochs HR, Greenblatt DJ, Woo E. Clinical pharmacokinetics of quinidine. Clin Pharmacokinet 1980;5(2):150-68.
85. Ochs HR, Greenblatt DJ, Woo E, Smith TW. Reduced quinidine clearance in elderly persons. Am J Cardiol 1978;42(3):481-5.
86. Fattinger K, Vozeh S, Ha HR, Borner M, Follath F. Population pharmacokinetics of quinidine. Br J Clin Pharmacol 1991;31(3):279-86.
87. Garfinkel D. Mamelok RD, Blaschke TF. Altered therapeutic range for quinidine after myocardial infarction and cardiac surgery. Ann Intern Med 1987;107(1):48-50.
88. Kessler KM, Lisker B, Conde C. Abnormal quinidine binding in survivors of prehospital cardiac arrest. Am Heart J 1984;107(4):665-9.
89. Kessler KM, Kissane B, Cassidy J. Dynamic variability of binding of antiarrhythmic drugs during the evolution of acute myocardial infarction. Circulation 1984;70(3):472-8.
90. Fremstad D, Nilsen OG, Storstein L, Amlie J, Jacobsen S. Pharmacokinetics of quinidine related to plasma protein binding in man. Eur J Clin Pharmacol 1979;15(3):187-92.
91. Davies RF, Dube LM, Mousseau N, McGilveray I, Beanlands DS. Perioperative variability of binding of lidocaine, quinidine, and propranolol after cardiac operations. J Thorac Cardiovasc Surg 1988;96(4):634-41.
92. Slaughter RL, Hassett JM. Hepatic drug clearance following traumatic injury. Drug Intell Clin Pharm 1985;19(11): 799-806.
93. Edwards DJ, Axelson JE, Slaughter RL, Elvin T, Lalka D. Factors affecting quinidine protein binding in humans. J Pharm Sci 1984;73(9):1264-7.
94. Kessler KM, Perez GO. Decreased quinidine plasma protein binding during hemodialysis. Clin Pharmacol Ther 1981;30(1):121-6.
95. Perez-Mateo M, Erill S. Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency. Eur J Clin Pharmacol 1977;11(3):225-31.
96. Trohman RG, Estes DM, Castellanos A, et al. Increased quinidine plasma concentrations during administration of verapamil: a new quinidine-verapamil interaction. Am J Cardiol 1986;57(8):706-7.
97. Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther 1988;26:388-91.
98. Marcus FI. Drug interactions with amiodarone. Am Heart J 1983;106:924-30.
99. Spinler SA, Cheng JW, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther. 1995;57(1):89-94.
100. Cooke CE, Sklar GE, Nappi JM. Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Ann Pharmacother 1996;30(4):364-6.
101. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995;15(4):263-9.
102. Ching MS, Blake CL, Ghabrial H, et al. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharmacol 1995;50(6):833-7.
103. Koren G, MacLeod SM. Characteristics of the digoxinquinidine and digoxin-verapamil interactions in the rat kidney. Res Commun Chem Pathol Pharmacol 1984;45(1):3-18.
104. Sheldon R, Duff H, Koshman ML. Antiarrhythmic activity of quinidine in humans. Circulation 1995;92(10):2944-50.
105. Berman ND, Dorian P. Cellular mechanism underlying the efficacy of the sotalol-quinidine combination. J Cardiovasc Pharmacol 1993;21(4):609-14.
106. Mariano DJ, Schomer SJ, Rea RF. Effects of quinidine on vascular resistance and sympathetic nerve activity in humans. J Am Coll Cardiol 1992;20(6):1411-16.
107. Gillis AM, Mitchell LB, Wyse DG, McDonald M, Duff HJ. Quinidine pharmacodynamics in patients with arrhythmia: effects of left ventricular function. J Am Coll Cardiol 1995;25(5):989-94.